Biopharma Stability Testing Laboratory Limited 08064938 false 2022-03-29 2023-03-28 2023-03-28 The principal activity of the company is consultancy and analytical services to support safe delivery of medical products to patients Digita Accounts Production Advanced 6.30.9574.0 true false 08064938 2022-03-29 2023-03-28 08064938 2023-03-28 08064938 bus:OrdinaryShareClass1 2023-03-28 08064938 bus:Revised 2023-03-28 08064938 core:CurrentFinancialInstruments 2023-03-28 08064938 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-28 08064938 core:Non-currentFinancialInstruments 2023-03-28 08064938 core:Non-currentFinancialInstruments core:AfterOneYear 2023-03-28 08064938 core:FurnitureFittingsToolsEquipment 2023-03-28 08064938 core:OtherPropertyPlantEquipment 2023-03-28 08064938 bus:SmallEntities 2022-03-29 2023-03-28 08064938 bus:AuditExemptWithAccountantsReport 2022-03-29 2023-03-28 08064938 bus:FullAccounts 2022-03-29 2023-03-28 08064938 bus:SmallCompaniesRegimeForAccounts 2022-03-29 2023-03-28 08064938 bus:RegisteredOffice 2022-03-29 2023-03-28 08064938 bus:Director1 2022-03-29 2023-03-28 08064938 bus:OrdinaryShareClass1 2022-03-29 2023-03-28 08064938 bus:PrivateLimitedCompanyLtd 2022-03-29 2023-03-28 08064938 core:FurnitureFittingsToolsEquipment 2022-03-29 2023-03-28 08064938 core:OfficeEquipment 2022-03-29 2023-03-28 08064938 core:OtherPropertyPlantEquipment 2022-03-29 2023-03-28 08064938 core:PlantMachinery 2022-03-29 2023-03-28 08064938 1 2022-03-29 2023-03-28 08064938 countries:England 2022-03-29 2023-03-28 08064938 2022-03-28 08064938 core:FurnitureFittingsToolsEquipment 2022-03-28 08064938 core:OtherPropertyPlantEquipment 2022-03-28 08064938 2021-03-29 2022-03-28 08064938 2022-03-28 08064938 bus:OrdinaryShareClass1 2022-03-28 08064938 core:CurrentFinancialInstruments 2022-03-28 08064938 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-28 08064938 core:Non-currentFinancialInstruments 2022-03-28 08064938 core:Non-currentFinancialInstruments core:AfterOneYear 2022-03-28 08064938 core:FurnitureFittingsToolsEquipment 2022-03-28 08064938 core:OtherPropertyPlantEquipment 2022-03-28 08064938 bus:OrdinaryShareClass1 2021-03-29 2022-03-28 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08064938

Biopharma Stability Testing Laboratory Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 28 March 2023

 

Biopharma Stability Testing Laboratory Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Biopharma Stability Testing Laboratory Limited

Company Information

Director

Dr A S Wilkinson

Registered office

Biocity
Pennyfoot Street
Nottingham
Nottinghamshire
NG1 1GF

Accountants

Vanilla Accounting Limited
Chartered Accountants
Appleton House
25 Rectory Road
West Bridgford
Nottingham
NG2 6BE

 

Biopharma Stability Testing Laboratory Limited

(Registration number: 08064938)
Balance Sheet as at 28 March 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

95,226

138,364

Current assets

 

Stocks

5

230,000

18,000

Debtors

6

171,856

357,034

Cash at bank and in hand

 

1

131,731

 

401,857

506,765

Creditors: Amounts falling due within one year

7

(193,288)

(182,269)

Net current assets

 

208,569

324,496

Total assets less current liabilities

 

303,795

462,860

Creditors: Amounts falling due after more than one year

7

(143,580)

(201,083)

Provisions for liabilities

(18,093)

(26,289)

Net assets

 

142,122

235,488

Capital and reserves

 

Called up share capital

8

2

2

Retained earnings

142,120

235,486

Shareholders' funds

 

142,122

235,488

For the financial year ending 28 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 3 October 2023
 

 

Biopharma Stability Testing Laboratory Limited

(Registration number: 08064938)
Balance Sheet as at 28 March 2023

.........................................
Dr A S Wilkinson
Director

 

Biopharma Stability Testing Laboratory Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 March 2023

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Biocity
Pennyfoot Street
Nottingham
Nottinghamshire
NG1 1GF

These financial statements were authorised for issue by the director on 3 October 2023.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Biopharma Stability Testing Laboratory Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 March 2023

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

33% straight line

20% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Biopharma Stability Testing Laboratory Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 March 2023

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 6 (2022 - 7).

 

Biopharma Stability Testing Laboratory Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 March 2023

4

tangible assets

Furniture, fittings and equipment
 £

Other tangible assets
£

Total
£

Cost or valuation

At 29 March 2022

34,667

297,966

332,633

Additions

-

2,422

2,422

At 28 March 2023

34,667

300,388

335,055

Depreciation

At 29 March 2022

30,157

164,112

194,269

Charge for the year

2,625

42,935

45,560

At 28 March 2023

32,782

207,047

239,829

Carrying amount

At 28 March 2023

1,885

93,341

95,226

At 28 March 2022

4,510

133,854

138,364

5

stocks

2023
£

2022
£

Work in progress

230,000

18,000

6

debtors

Current

2023
£

2022
£

Trade debtors

158,198

334,980

Prepayments

4,735

3,272

Other debtors

8,923

18,782

 

171,856

357,034

7

Creditors

Creditors: amounts falling due within one year

 

Biopharma Stability Testing Laboratory Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 March 2023

Note

2023
£

2022
£

Due within one year

 

Loans and borrowings

9

130,670

59,000

Trade creditors

 

1,100

5,521

Taxation and social security

 

16,532

35,664

Accruals and deferred income

 

15,466

2,733

Other creditors

 

29,520

79,351

 

193,288

182,269

Creditors include bank loans and overdrafts and net obligations under finance lease and hire purchase contracts which are secured of £111,670 (2022 - £40,000).

Creditors: amounts falling due after more than one year

Note

2023
£

2022
£

Due after one year

 

Loans and borrowings

9

143,580

201,083

Creditors include bank loans and overdrafts and net obligations under finance lease and hire purchase contracts which are secured of £88,163 (2022 - £126,667 ).

8

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary shares of £1 each

2

2

2

2

         

9

Loans and borrowings

2023
£

2022
£

Non-current loans and borrowings

Bank borrowings

88,163

126,667

Other borrowings

55,417

74,416

143,580

201,083

 

Biopharma Stability Testing Laboratory Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 March 2023

2023
£

2022
£

Current loans and borrowings

Bank borrowings

39,184

40,000

Bank overdrafts

72,486

-

Other borrowings

19,000

19,000

130,670

59,000

10

Dividends

Interim dividends paid

   

2023
£

 

2022
£

Interim dividend of £2,000.00 (2022 - £22,000.00) per each Ordinary shares

 

4,000

 

44,000

         

11

Financial commitments, guarantees and contingencies

Amounts disclosed in the balance sheet

Included in the balance sheet are guarantees of £72,486 (2022 - £Nil). The director has provided a personal guarantee in respect of the company's bank overdraft.

12

Parent and ultimate parent undertaking

The ultimate controlling party is Mr AS Wilkinson and Mr MC Allwood.